New Jersey-based pharma companies joined White House drug pricing deals aimed at lowering prescription drug costs under Trump’s policy.

Yield, sector focus, and risk profiles set these two dividend ETFs apart—see how their distinct strategies may fit different investor goals.

Merck shares began peeling back in early 2024, mostly on concerns about looming patent expirations for its breadwinning drug. The trading crowd changed its collective mind a couple months ago, sending ...

For the better part of a year, Merck & Co. and Halozyme have been locked in an intellectual property disagreement over the the pharma giant's new, under-the-skin version of cancer megablockbuster ...